Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;14(4):238-250.
doi: 10.1038/nrcardio.2016.203. Epub 2016 Dec 22.

Expert consensus document: Mitochondrial function as a therapeutic target in heart failure

David A Brown  1 , Justin B Perry  1 , Mitchell E Allen  1 , Hani N Sabbah  2 , Brian L Stauffer  3 , Saame Raza Shaikh  4 , John G F Cleland  5 , Wilson S Colucci  6 , Javed Butler  7 , Adriaan A Voors  8 , Stefan D Anker  9 , Bertram Pitt  10 , Burkert Pieske  11 , Gerasimos Filippatos  12 , Stephen J Greene  13 , Mihai Gheorghiade  14
Affiliations
Review

Expert consensus document: Mitochondrial function as a therapeutic target in heart failure

David A Brown et al. Nat Rev Cardiol. 2017 Apr.

Abstract

Heart failure is a pressing worldwide public-health problem with millions of patients having worsening heart failure. Despite all the available therapies, the condition carries a very poor prognosis. Existing therapies provide symptomatic and clinical benefit, but do not fully address molecular abnormalities that occur in cardiomyocytes. This shortcoming is particularly important given that most patients with heart failure have viable dysfunctional myocardium, in which an improvement or normalization of function might be possible. Although the pathophysiology of heart failure is complex, mitochondrial dysfunction seems to be an important target for therapy to improve cardiac function directly. Mitochondrial abnormalities include impaired mitochondrial electron transport chain activity, increased formation of reactive oxygen species, shifted metabolic substrate utilization, aberrant mitochondrial dynamics, and altered ion homeostasis. In this Consensus Statement, insights into the mechanisms of mitochondrial dysfunction in heart failure are presented, along with an overview of emerging treatments with the potential to improve the function of the failing heart by targeting mitochondria.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Energy supply–demand matching in health and heart failure
The delicate balance between cardiac demands for energy and supply of energy is tipped in heart failure, in which energy supply cannot match demand. Next-generation therapeutics can improve on existing standard-of-care therapies by bolstering mitochondrial energy production. ACE, angiotensin-converting enzyme; ARB, angiotensin II-receptor blocker; ETC, electron transport chain; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ROS, reactive oxygen species.
Figure 2
Figure 2. Impaired mitochondrial capacity and function in heart failure
Decreased capacity of mitochondria to generate and transfer energy within heart cells results in energy deficits, which influences all cellular processes that require energy, most notably the processes of contraction and relaxation.
Figure 3
Figure 3. Mitochondrial contribution across multifaceted symptoms of heart failure
Aberrant mitochondrial energy production is involved in many symptoms commonly found in patients with heart failure, including skeletal muscle dysfunction and renal pathologies. LV, left ventricular.
Figure 4
Figure 4. Impaired mitochondrial energy production along the inner membrane
Enzyme complexes responsible for energy production are packed into the mitochondrial inner membrane, often with the help of phospholipids such as cardiolipin. Failing mitochondria often display altered morphology, decreased ATP-generating capacity, heightened production of reactive oxygen species (ROS), abnormal cardiolipin levels, and impaired supercomplexes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jessup M, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016. - PubMed
    1. Hunt SA, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235. - PubMed
    1. Wilcox JE, et al. “Targeting the Heart” in heart failure: myocardial recovery in heart failure with reduced ejection fraction. JACC Heart Fail. 2015;3:661–669. - PubMed
    1. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace. 2011;13:i13–ii17. - PubMed
    1. Yancy CW, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62:e147–e239. - PubMed

Publication types

MeSH terms

Supplementary concepts